Mulberroside A
Based on 4 publication(s) in Google Scholar
Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory antiapoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC50 of 53.6 μM.
For research use only. We do not sell to patients.
- Purity: 99.92%
- CAS No.: 102841-42-9
- Formula: C26H32O14
- Molecular Weight:568.52
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
NF-κB Signaling Compound Library
HY-L014
-
Natural Product Library
HY-L021
-
Anti-Cancer Compound Library
HY-L025
-
Differentiation Inducing Compound Library
HY-L038
-
Glycoside Compound Library
HY-L042
-
Medicine Food Homology Compound Library
HY-L055
-
Phenols Library
HY-L057
-
Pyroptosis Compound Library
HY-L059
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Cancer Natural Product Library
HY-L107
-
Antidepressant Compound Library
HY-L108
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Mitochondrial Protection Compound Library
HY-L144
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Miao Ethnicity Medicine Compound Library
HY-L190
-
PBCRBS Traditional Chinese Medicine Compound Library
HY-L193
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library
HY-L223
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Mulberroside A
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
IF
-
WB
-
RT-PCR
-
IHC
Biological Activity
|
IL-1β |
IL-6 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Kun-Ming mice (20±2 g)[4]
-
Dosage:5, 10, 20, and 40 mg/kg; the dose volume 10 mL/kg body weight
-
Administration:Orally initiated at 9:00 a.m.
-
Result:10, 20, and 40 mg/kg significantly increased urinary urate excretion in 24 h, resulting in a remarkable elevation of fractional excretion of uric acid (FEUA), and the highest dose completely reversed FEUA alteration of hyperuricemic mice to normal.
Chemical Information
-
CAS No. 102841-42-9
-
Appearance Solid
-
Molecular Weight 568.52
-
Formula C26H32O14
-
Color White to off-white
-
SMILES
O[C@H]([C@@H](O)[C@@H]1O)[C@@H](O[C@@H]1CO)OC2=CC(/C=C/C(C=CC(O[C@@H]([C@@H]([C@@H](O)[C@@H]3O)O)O[C@@H]3CO)=C4)=C4O)=CC(O)=C2
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
Apolipoprotein C3 (ApoC3) facilitates NLRP3 mediated pyroptosis of macrophages through mitochondrial damage by accelerating of the interaction between SCIMP and SYK pathway in acute lung injury. [Abstract]2024 Feb 15:128:111537. PMID: 38232538 -
J Inflamm (Lond)
Mulberroside A mitigates intervertebral disc degeneration by inhibiting MAPK and modulating Ppar-γ/NF-κB pathways. [Abstract]2024 Aug 28;21(1):32. PMID: 39198816
Mulberroside A purchased from MedChemExpress. Usage Cited in: J Inflamm (Lond). 2024 Aug 28;21(1):32. [Abstract]
The viability of NPCs intervened with different Mulberroside A (MA) concentrations (0, 20, 40, 80, and 160 µM) for 24 h was evaluated by a CCK-8 kit.
Mulberroside A purchased from MedChemExpress. Usage Cited in: J Inflamm (Lond). 2024 Aug 28;21(1):32. [Abstract]
A Calcein /PI double staining of NPCs after intervention with IL-1β (5 ng/mL) alone or with different Mulberroside A (MA) concentrations (20, 40, and 80 µM) for 24 h.
Mulberroside A purchased from MedChemExpress. Usage Cited in: J Inflamm (Lond). 2024 Aug 28;21(1):32. [Abstract]
The inflammatory proteins expressions (Inos, Cox-2, and Il-6) in NPCs shown in western blotting treated with Mulberroside A (MA) (20, 40, 80 μM).
Mulberroside A purchased from MedChemExpress. Usage Cited in: J Inflamm (Lond). 2024 Aug 28;21(1):32. [Abstract]
The mRNA expression levels of inflammatory genes (Inos and Cox-2) were analyzed by RT-qPCR treated with Mulberroside A (MA) (20, 40, 80 μM).
Mulberroside A purchased from MedChemExpress. Usage Cited in: J Inflamm (Lond). 2024 Aug 28;21(1):32. [Abstract]
IHC images of Aggrecan, Mmp13, Collagen II, Ppar-γ treated with Mulberroside A (MA) (80 μM).
-
iScience
Mulberroside A alleviates osteoarthritis via restoring impaired autophagy and suppressing MAPK/NF-κB/PI3K-AKT-mTOR signaling pathways. [Abstract]2023 Jan 5;26(2):105936. PMID: 36698724 -
Solvent & Solubility
DMSO : 50 mg/mL (87.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 10 mg/mL (17.59 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Mei M, et al. In vitro pharmacokinetic characterization of mulberroside A, the main polyhydroxylated stilbene in mulberry (Morus alba L.), and its bacterial metabolite oxyresveratrol in traditional oral use. J Agric Food Chem. 2012 Mar 7;60(9):2299-308. [Content Brief]
[2]. Wang CP, et al. Mulberroside A protects against ischemic impairment in primary culture of rat cortical neurons after oxygen-glucose deprivation followed by reperfusion. J Neurosci Res. 2014 Jul;92(7):944-54. [Content Brief]
[3]. Kim JK, et al. Biotransformation of mulberroside A from Morus alba results in enhancement of tyrosinase inhibition. J Ind Microbiol Biotechnol. 2010 Jun;37(6):631-7. [Content Brief]
[4]. Cai-Ping Wang,et al. Mulberroside a possesses potent uricosuric and nephroprotective effects in hyperuricemic mice. Planta Med. 2011 May;77(8):786-94. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7590 mL | 8.7948 mL | 17.5895 mL | 43.9738 mL |
| 5 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL | 8.7948 mL | |
| 10 mM | 0.1759 mL | 0.8795 mL | 1.7590 mL | 4.3974 mL | |
| 15 mM | 0.1173 mL | 0.5863 mL | 1.1726 mL | 2.9316 mL | |
| 20 mM | 0.0879 mL | 0.4397 mL | 0.8795 mL | 2.1987 mL | |
| 25 mM | 0.0704 mL | 0.3518 mL | 0.7036 mL | 1.7590 mL | |
| 30 mM | 0.0586 mL | 0.2932 mL | 0.5863 mL | 1.4658 mL | |
| 40 mM | 0.0440 mL | 0.2199 mL | 0.4397 mL | 1.0993 mL | |
| 50 mM | 0.0352 mL | 0.1759 mL | 0.3518 mL | 0.8795 mL | |
| 60 mM | 0.0293 mL | 0.1466 mL | 0.2932 mL | 0.7329 mL | |
| 80 mM | 0.0220 mL | 0.1099 mL | 0.2199 mL | 0.5497 mL |
Powered by Bioz